Meet this week’s guest, Olivier Delporte, the CEO of SamanTree Medical. He joined me, your host, Henry Norton, to discuss his company’s game-changing imaging technology, which is set to improve surgical outcomes for cancer patients in the breast and prostate areas. 

Oliver also has an extensive background in venture capital, which he says compliments his role as CEO, as it allows him to build the company to a point that it is attractive to investors. 

He also discussed the innovations behind the Histolog Scanner, including the current imaging systems and their failings, which prompted SamanTree Medical to create their device in the first place. 

Oliver also focuses on patient outcomes, citing the lowered need for reintervention as one of his company’s scanners’ biggest achievements, particularly when treating breast cancer. 

He shared some of the wider applications that the scanner could be used for, including lung, urology and thoracic procedures. 

Key Topics: 

• Oliver’s background and career journey, including the insights he’s gained from it 

• Venture capitalists’ interest in medical technology 

• The Histolog Scanner and its clinical purposes 

• The impact of AI on the scanner’s further development 

Related Insights: 

• The benefits of clinical data for market expansion 

• Commercialisation strategies 

• The need for high-performing people in smaller startups 

Core Challenges:

• Previous imaging procedures, such as frozen section analysis, aren’t suitable for current clinical needs. Surgeons need faster, more reliable imaging systems in order to make the best decisions for their patients and provide better outcomes for the people in their care. 

• The Histolog Scanner provides faster imaging services and is set to provide readings, analysis and other support as AI technology advances. This will help surgeons make faster and better decisions while operating. 

Listen in to this fascinating episode that covers everything from funding and partnerships to human interest stories and life-altering surgical procedures.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠ ⁠click here.⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠TTP plc⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠TTP plc⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠TTP.com⁠⁠⁠⁠

&

⁠KUKA⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠kuka.com/healthcare